241 related articles for article (PubMed ID: 31826682)
1. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
[TBL] [Abstract][Full Text] [Related]
3. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
4. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
6. Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis.
Terao C; Yamakawa N; Yano K; Markusse IM; Ikari K; Yoshida S; Furu M; Hashimoto M; Ito H; Fujii T; Ohmura K; Murakami K; Takahashi M; Hamaguchi M; Tabara Y; Taniguchi A; Momohara S; Raychaudhuri S; Allaart CF; Yamanaka H; Mimori T; Matsuda F
Arthritis Rheumatol; 2015 Dec; 67(12):3113-23. PubMed ID: 26245322
[TBL] [Abstract][Full Text] [Related]
7. A simplified baseline prediction model for joint damage progression in rheumatoid arthritis: a step toward personalized medicine.
de Punder YM; van Riel PL; Fransen J
J Rheumatol; 2015 Mar; 42(3):391-7. PubMed ID: 25593237
[TBL] [Abstract][Full Text] [Related]
8. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of rheumatoid arthritis by magnetic resonance imaging in the absence of anti-cyclic citrullinated peptide antibodies and radiographic erosions in undifferentiated inflammatory arthritis patients: a prospective study.
Ji L; Li G; Xu Y; Zhou W; Zhang Z
Int J Rheum Dis; 2015 Nov; 18(8):859-65. PubMed ID: 25483781
[TBL] [Abstract][Full Text] [Related]
10. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.
Bøyesen P; Hoff M; Odegård S; Haugeberg G; Syversen SW; Gaarder PI; Okkenhaug C; Kvien TK
Arthritis Res Ther; 2009; 11(4):R103. PubMed ID: 19570223
[TBL] [Abstract][Full Text] [Related]
12. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
13. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Orbach H; Gerli R; Shoenfeld Y
Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
[TBL] [Abstract][Full Text] [Related]
15. Anti-cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound-detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity.
Tan YK; Li H; Allen JC; Thumboo J
Int J Rheum Dis; 2020 Oct; 23(10):1337-1343. PubMed ID: 33460311
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
[TBL] [Abstract][Full Text] [Related]
17. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint.
Meeuwisse CM; van der Linden MP; Rullmann TA; Allaart CF; Nelissen R; Huizinga TW; Garritsen A; Toes RE; van Schaik R; van der Helm-van Mil AH
Arthritis Rheum; 2011 May; 63(5):1265-73. PubMed ID: 21305530
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N; Chiba K; Sato S; Shiraishi K; Watanabe K; Oki N; Okada A; Koga T; Kawashiri SY; Tamai M; Hosogaya N; Furuyama M; Kobayashi M; Saito K; Okubo N; Uetani M; Osaki M; Kawakami A
Arthritis Res Ther; 2022 Dec; 24(1):264. PubMed ID: 36476479
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
20. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
